Johnson & Johnson (NYSE: JNJ) named among 14 Best Dividend Growth Stocks to Buy and Hold in 2026. Barclays raises JNJ target to $217 from $197, citing strength in key drugs like Darzalex, Tremfya, and Simponi. The company continues to invest heavily in R&D, recently acquiring Halda Therapeutics for $3.1 billion to advance cancer treatment.

Oncology remains a core strength for JNJ, with key products like Rybrevant and Lazcluze targeting advanced non-small cell lung cancer. Inlexzo, developed for bladder cancer, expected to boost oncology portfolio. JNJ focuses on research, development, manufacturing, and sale of healthcare products worldwide.

While JNJ shows investment potential, some AI stocks offer greater upside with less downside risk. For an undervalued AI stock benefiting from Trump-era tariffs and the onshoring trend, see the report on the best short-term AI stock. Explore 12 Best Income Stocks to Buy Now and 20 Best Performing Dividend Stocks in 2025 for more investment opportunities. No disclosure provided.

Read more at Yahoo Finance: Barclays Raises Johnson & Johnson (JNJ) Target on Strength in Key Drugs